Literature DB >> 24977470

Activators of PKA and Epac distinctly influence insulin secretion and cytosolic Ca2+ in female mouse islets stimulated by glucose and tolbutamide.

Jean-Claude Henquin1, Myriam Nenquin.   

Abstract

Amplification of insulin secretion by cAMP is mediated by protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). Using selective activators, we determined how each effector influences the cytosolic free Ca(2+) concentration ([Ca(2+)]c) and insulin secretion in mouse islets. Alone PKA activator amplified glucose- and tolbutamide-induced insulin secretion, with a greater impact on second than first phase. Epac activator strongly amplified both phases in response to either secretagogue. Amplification was even greater when activators were combined. Although both activators similarly amplified glucose-induced insulin secretion, Epac activator was particularly efficient on tolbutamide-induced insulin secretion. That greater efficacy is attributed to higher [Ca(2+)]c rather than interaction of tolbutamide with Epac, because it was also observed during KCl stimulation. Moreover, in contrast to Epac activator, tolbutamide was inactive when insulin secretion was increased by gliclazide, and its effect on glucose-induced insulin secretion was unaffected by an inhibitor of Epac2. PKA activator increased [Ca(2+)]c during acute or steady-state glucose stimulation, whereas Epac activator had no effect alone or in combination. Neither activator affected [Ca(2+)]c response to tolbutamide or KCl. Metabolic (glucose-mediated) amplification of insulin secretion was unaffected by PKA activator. It was attenuated when insulin secretion was augmented by Epac activator but insensitive to Epac2 inhibitor, which suggests distinct although somewhat overlapping mechanisms. In conclusion, activators of PKA and Epac amplify insulin secretion by augmenting the action of Ca(2+) on exocytosis and, for PKA only, slightly increasing glucose-induced [Ca(2+)]c rise. The influence of Epac seems more important than that of PKA during first phase.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24977470      PMCID: PMC4255079          DOI: 10.1210/en.2014-1247

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  59 in total

1.  Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells.

Authors:  Guoxin Kang; Jamie W Joseph; Oleg G Chepurny; Marie Monaco; Michael B Wheeler; Johannes L Bos; Frank Schwede; Hans-G Genieser; George G Holz
Journal:  J Biol Chem       Date:  2002-12-20       Impact factor: 5.157

2.  Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP.

Authors:  Tadao Shibasaki; Harumi Takahashi; Takashi Miki; Yasuhiro Sunaga; Kimio Matsumura; Mami Yamanaka; Changliang Zhang; Atsuko Tamamoto; Takaya Satoh; Jun-Ichi Miyazaki; Susumu Seino
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

3.  8-pCPT-2'-O-Me-cAMP-AM: an improved Epac-selective cAMP analogue.

Authors:  Marjolein J Vliem; Bas Ponsioen; Frank Schwede; Willem-Jan Pannekoek; Jurgen Riedl; Matthijs R H Kooistra; Kees Jalink; Hans-Gottfried Genieser; Johannes L Bos; Holger Rehmann
Journal:  Chembiochem       Date:  2008-09-01       Impact factor: 3.164

4.  cAMP-GEFII is a direct target of cAMP in regulated exocytosis.

Authors:  N Ozaki; T Shibasaki; Y Kashima; T Miki; K Takahashi; H Ueno; Y Sunaga; H Yano; Y Matsuura; T Iwanaga; Y Takai; S Seino
Journal:  Nat Cell Biol       Date:  2000-11       Impact factor: 28.824

5.  SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells.

Authors:  Lena Eliasson; Xiaosong Ma; Erik Renström; Sebastian Barg; Per-Olof Berggren; Juris Galvanovskis; Jesper Gromada; Xingjun Jing; Ingmar Lundquist; Albert Salehi; Sabine Sewing; Patrik Rorsman
Journal:  J Gen Physiol       Date:  2003-03       Impact factor: 4.086

Review 6.  Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors.

Authors:  George G Holz; Oleg G Chepurny; Frank Schwede
Journal:  Cell Signal       Date:  2007-07-25       Impact factor: 4.315

Review 7.  Regulation of insulin secretion: a matter of phase control and amplitude modulation.

Authors:  J C Henquin
Journal:  Diabetologia       Date:  2009-03-14       Impact factor: 10.122

8.  The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs.

Authors:  Chang-Liang Zhang; Megumi Katoh; Tadao Shibasaki; Kohtaro Minami; Yasuhiro Sunaga; Harumi Takahashi; Norihide Yokoi; Masahiro Iwasaki; Takashi Miki; Susumu Seino
Journal:  Science       Date:  2009-07-31       Impact factor: 47.728

9.  cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension.

Authors:  Anne E Christensen; Frode Selheim; Johan de Rooij; Sarah Dremier; Frank Schwede; Khanh K Dao; Aurora Martinez; Carine Maenhaut; Johannes L Bos; H-G Genieser; Stein O Døskeland
Journal:  J Biol Chem       Date:  2003-06-20       Impact factor: 5.157

Review 10.  Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.

Authors:  Bo Ahrén
Journal:  Nat Rev Drug Discov       Date:  2009-04-14       Impact factor: 84.694

View more
  15 in total

1.  Rp-cAMPS Prodrugs Reveal the cAMP Dependence of First-Phase Glucose-Stimulated Insulin Secretion.

Authors:  Frank Schwede; Oleg G Chepurny; Melanie Kaufholz; Daniela Bertinetti; Colin A Leech; Over Cabrera; Yingmin Zhu; Fang Mei; Xiaodong Cheng; Jocelyn E Manning Fox; Patrick E MacDonald; Hans-G Genieser; Friedrich W Herberg; George G Holz
Journal:  Mol Endocrinol       Date:  2015-06-10

Review 2.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

3.  Exendin-4 overcomes cytokine-induced decreases in gap junction coupling via protein kinase A and Epac2 in mouse and human islets.

Authors:  Nikki L Farnsworth; Rachelle Walter; Robert A Piscopio; Wolfgang E Schleicher; Richard K P Benninger
Journal:  J Physiol       Date:  2018-11-29       Impact factor: 5.182

4.  Cyclic AMP-dependent protein kinase A and EPAC mediate VIP and secretin stimulation of PAK4 and activation of Na+,K+-ATPase in pancreatic acinar cells.

Authors:  Irene Ramos-Alvarez; Lingaku Lee; R T Jensen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-12-06       Impact factor: 4.052

5.  Glycine Release Is Potentiated by cAMP via EPAC2 and Ca2+ Stores in a Retinal Interneuron.

Authors:  Marc A Meadows; Veeramuthu Balakrishnan; Xiaohan Wang; Henrique von Gersdorff
Journal:  J Neurosci       Date:  2021-10-07       Impact factor: 6.167

Review 6.  Role of cAMP and phosphodiesterase signaling in liver health and disease.

Authors:  Banrida Wahlang; Craig McClain; Shirish Barve; Leila Gobejishvili
Journal:  Cell Signal       Date:  2018-06-11       Impact factor: 4.315

Review 7.  The future of EPAC-targeted therapies: agonism versus antagonism.

Authors:  Euan Parnell; Timothy M Palmer; Stephen J Yarwood
Journal:  Trends Pharmacol Sci       Date:  2015-03-03       Impact factor: 14.819

8.  Sucralose activates an ERK1/2-ribosomal protein S6 signaling axis.

Authors:  Marcy L Guerra; Michael A Kalwat; Kathleen McGlynn; Melanie H Cobb
Journal:  FEBS Open Bio       Date:  2017-01-18       Impact factor: 2.693

Review 9.  Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men.

Authors:  Patrik Rorsman; Frances M Ashcroft
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

10.  The Capacity to Secrete Insulin Is Dose-Dependent to Extremely High Glucose Concentrations: A Key Role for Adenylyl Cyclase.

Authors:  Katherine M Gerber; Nicholas B Whitticar; Daniel R Rochester; Kathryn L Corbin; William J Koch; Craig S Nunemaker
Journal:  Metabolites       Date:  2021-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.